Tenofovir rescue therapy in pregnant females with chronic hepatitis B

Table 1 Characteristics of 17 pregnant women with chronic hepatitis B treated with tenofovir

IDNo.	Age(yr)	Pregestationalanti-HBV treatment	GW starting TDF	Pre-TDF studies				Duration of TDF before delivery(wk)	Studies performed at delivery
				ALT(U/L)	HBV DNA(log10 copies/mL)	Cr(μmol/L)	Pho(mmol/L)		ALT(U/L)	HBVi DNA(log10 copies/mL)	Cr(μmol/L)	Phok(mmol/L)
1	32	LAM	26	66.4	7.2	39.0	1.28	12	10.8	2.9	49.0	1.19
2	37	LAM	20	28.9	4.4	62.8	1.08	20	19.8	< 2.7	64.3	1.10
3	31	ETV→LAM	24	39.1	5.1	60.4	1.12	14	25.8	< 2.7	57.7	1.00
4	30	LAM→ADVc + LAM	5	35.5	4.2	47.6	1.24	35	28.0	< 2.7	54.8	0.94
5	31	LAM→ADV→LAM	0	97.4	6.4	45.3	1.03	40	15.5	< 2.7	60.5	1.19
6	28	ADV→ADV + LAM→LAM	16	15.4	5.9	40.0	1.35	24	10.9	< 2.7	47.7	1.10
7	31	LdT	22	51.6	5.6	50.4	1.21	17	21.1	< 2.7	49.9	0.96
8	30	LdT	12	40.1	5.4	64.8	1.20	28	12.5	< 2.7	60.7	0.92
9	32	LdT	10	170.2	6.3	37.0	0.97	28	8.8	< 2.7	40.0	0.73
10	30	LdT	0	22.4	5.7	57.5	1.11	39	19.4	< 2.7	55.2	1.35
11	31	LdT	16	42.0	6.1	44.3	1.10	24	28.4	< 2.7	48.9	1.32
12	25	INF→LdT	8	131.0	5.6	69.2	1.23	32	20.0	< 2.7	51.0	0.95
13	28	LAM→LdT	20	264.21	6.1	52.7	0.83	19	23.7	< 2.7	47.0	0.95
14	28	LAM→LdT	28	15.8	6.4	43.3	1.16	12	15.5	3.0	46.8	0.98
15	29	ADV→LAM→LdT	27	15.8	5.3	73.3	1.02	12	30.0	3.8	51.6	0.90
16	33	LdT→ETV + ADV→LdT	5	213.0	6.6	56.4	0.99	35	24.0	< 2.7	46.9	1.28
17	34	LAM→ADV + LAM→LdT	16	1701.6	6.9	42.7	0.96	23	16.1	< 2.7	56.3	0.87

LAM: Lamivudine; ETV: Entecavir; ADV: Adefovir; LdT: Telbivudine; INF: Interferon; TDF: Tenofovir; GW: Gestational week; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; Cr: Creatinine; Pho: Serum phosphorus.